99mTc(V)-DMSA scintigraphy in monitoring the response of bone disease to vitamin D3 therapy in renal osteodystrophy
Küçük Resim Yok
Tarih
2002
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Springer
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Renal osteodystrophy (ROD) is a common and serious complication for uremic patients and patients are treated with 1,25-dihydroxy vitamin D-3. The bone scanning agent Tc-99m-phosphate has also been used to evaluate in ROD but it is not clear that bone scintigraphy has a role in the follow-up of treatment. In this study Tc-99m(V)-DMSA scintigraphy was performed in eleven patients [age 40.7 +/- 17.3 (mean +/- SD) yr] with ROD before and after vitamin D-3 therapy. Images were obtained after hemodialysis performed following tracer injection to maintain normal blood levels of the radiopharmaceutical and to reduce soft tissue activity. Lumbar vertebra-to-soft tissue uptake ratios (LUR) were quantified with the planar Tc-99m(V)-DMSA images. Alkaline phosphatase and parathyroid hormone levels after treatment had significantly decreased compared with pre-therapy. In all patients there was visually decreased uptake in bone structures after treatment. After treatment the mean LUR ratio was significantly lower than those of before treatment (3.59 +/- 2.63 vs. 1.65 +/- 0.62; p = 0.01). LUR values were correlated with pre-therapy alkaline phosphatase and parathyroid hormone. These findings indicate that Tc-99m(V)-DMSA scintigraphy is sensitive in evaluating the response of ROD to vitamin D-3 therapy.
Açıklama
Anahtar Kelimeler
Renal Osteodystrophy, Scintigraphy, Tc-99m(V)-DMSA, Tc-99m Dimercaptosuccinic Acid, Whole-Body Retention, Concise Communication, Hyperparathyroidism, Metabolism, Failure, Spect, Scan
Kaynak
Annals Of Nuclear Medicine
WoS Q Değeri
Q4
Scopus Q Değeri
Q2
Cilt
16
Sayı
1
